Home › Trials › NCT06787612

Ubamatamab alone and with other cancer drugs for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Phase 2 Interventional Regeneron Pharmaceuticals · NCT06787612

This trial will test whether ubamatamab by itself or combined with bevacizumab, cemiplimab, fianlimab, or pegylated liposomal doxorubicin helps adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment220 (estimated)
Ages18 Years and up
SexFemale
SponsorRegeneron Pharmaceuticals Industry-sponsored
Drugs / interventionsdoxorubicin, ubamatamab, bevacizumab, cemiplimab, fianlimab, chemotherapy
Locations50 sites (Birmingham, Alabama and 49 other locations)
Trial IDNCT06787612 on ClinicalTrials.gov

What this trial studies

This phase 2, multi-center trial gives adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer ubamatamab either alone or paired with bevacizumab, cemiplimab, fianlimab, or pegylated liposomal doxorubicin (PLD). The study will monitor safety, tolerability, anti-tumor activity, blood levels of the drugs, and whether the body develops antibodies against the treatments. Eligible participants must have measurable disease by RECIST 1.1, ECOG performance status 0–1, and adequate organ and bone marrow function. Research visits occur at participating U.S. centers and include regular imaging and laboratory testing to track response and side effects.

Who should consider this trial

Good fit: Adults with histologically or cytologically confirmed advanced serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer that is platinum-resistant, with at least one measurable lesion, ECOG 0–1, and adequate organ and marrow function are ideal candidates.

Not a fit: Patients with excluded histologies (clear cell, mucinous, carcinosarcoma), recent major surgery or trauma, known severe allergies to antibody therapies or doxorubicin components, poor performance status, or without measurable disease are unlikely to qualify or benefit.

Why it matters

Potential benefit: If successful, the regimen could provide a new treatment option that improves tumor control for people with platinum-resistant disease.

How similar studies have performed: Other antibody combinations and immune checkpoint approaches have shown activity in some platinum-resistant ovarian cancer trials, but ubamatamab and its specific combinations are relatively new and not yet proven effective.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

1. Participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian (regardless of the grade), primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded)
2. Must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by RECIST 1.1
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4. Adequate organ and bone marrow function, as described in the protocol
5. Platinum-Resistant Ovarian Cancer, as described in the protocol

Key Exclusion Criteria:

1. Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study intervention(s)
2. Documented allergic or acute hypersensitivity reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study intervention(s)
3. Another malignancy that is progressing or requires active treatment, as described in the protocol
4. Untreated or active Central Nervous System (CNS) metastases, or carcinomatous meningitis, as described in the protocol
5. Uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency
6. Moderate to large or ascites, as described in the protocol
7. Bowel obstruction within last 3 months or current need for parenteral nutrition

NOTE: Other protocol-defined inclusion/exclusion criteria apply

Where this trial is running

Birmingham, Alabama and 49 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerPlatinum Resistance
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.